Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−7.98%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

29.18 0.27 −0.92%
Market cap
$170.3B
P/E
42.2×
Fwd P/E
18.9×
Dividend yield
7.18%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
ROE
4.42% 4.97% 8.28% 8.87%

+8 more TTM periods

Piotroski F-Score
5 6 5 6
ROA
1.95% 2.13% 3.60% 3.69%
ROIC
6.19% 6.30% 6.41% 6.45%
Return on Tangible Assets
12.48% 15.62% 26.87% 30.80%
Average Days of Receivables
81.42 71.57 72.55 69.26
Free Cash Flow per Share
2.07 1.93 1.67 1.60
Free Cash Flow
11,786.00 10,985.00 9,483.00 9,075.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026